Radial Ablation for the Control of Persistent Atrial Fibrillation (ARTIST)

Radial Ablation for the Control of Persistent Atrial Fibrillation (Ablación Radial Para ConTrol De La Fibrilación Auricular PersISTtente)

The protocol aims to evaluate the efficacy of the radial ablation technique of the maintenance mechanisms in persistent atrial fibrillation compared to the isolation of the pulmonary veins evaluating the atrial fibrillation burden during one year follow-up.

Study Overview

• Status: Active, not recruiting
• Conditions: Persistent Atrial Fibrillation
• Intervention / Treatment: Procedure: Pulmonary vein electrical isolation; Procedure: Radial ablation

Detailed Description

Atrial fibrillation is the most common arrhythmia in clinical practice, and its treatment still remains suboptimal. Electrical isolation of the pulmonary veins with radiofrequency ablation or cryoablation is the standard therapy when antiarrhythmic drugs or electrical cardioversion is not successful. However, recurrence after catheter ablation worsens in persistent and permanent atrial fibrillation patients. Recently, rotational activity electrogram patterns of self-sustained electrical activity found in the atria have been proposed as the responsible mechanism for the maintenance of atrial fibrillation. The investigators devised a controlled, multicentric, prospective, not blinded, and randomized clinical trial with the aim of comparing pulmonary vein catheter ablation versus radial ablation of sites exhibiting rotational activity in patients with persistent atrial fibrillation. Radial ablation consists of the ablation of the rotational activity sites and an additional ablation line connecting the rotation site with the circumferential ablation line of the pulmonary veins.

Besides, subanalysis ARTIST-Gender and ARTIST-HF will be performed. ARTIST-Gender will compare the same outcomes and analysis of the patient cohort but according to the gender of the patient, and ARTIST-HF will sub-divide the analysis with respect to heart failure present in the enrolled patients' cohort.

• Study Type: Interventional
• Enrollment (Estimated): 244
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Madrid, Spain, 28041
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28009
    • Hospital General Universitario Gregorio Marañón
  • Madrid
    • Majadahonda, Madrid, Spain, 28222
      • Hospital Universitario Puerta de Hierro

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years and ≤ 75 years.
• Non-valvular symptomatic persistent atrial fibrillation.
• Patient willingness to participate in the study providing signed written informed consent.
• Failure or drug intolerance or refusal to continue with chronic antiarrhythmic treatment.
• Left ventricular ejection fraction LVEF) ≥ 25 % in the last echocardiogram prior to enrollment.

Exclusion Criteria:

• Left atrial diameter > 5.5 cm in the last echocardiogram.
• Contraindication of chronic anticoagulation or heparin.
• Previous atrial fibrillation ablation procedure.
• Acute coronary syndrome, cardiac surgery or acute cerebrovascular accident in two months prior to enrollement.
• Previous diagnosis for hyperthyroidism or hypothyroidism.
• Mental or physical illness that disables the patient to participate in the study.
• Scheduled cardiac percutaneous or surgical intervention.
• Non-controlled hypertension > 160/100.
• Terminal renal insufficiency or dialysis.
• Functional class IV of the New York Heart Association (NYHA).
• Moderate valvular disease or previous mitral prosthesis.
• Previous hypertrophic heart disease.
• Life expectancy less than 12 months.
• Inclusion on the transplant list.
• Participation in another study so as not to interfere with the results.
• Previous atrioventricular block.
• Pericardial effusion.
• Pregnancy or childbearing age without contraceptive treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control arm. Pulmonary vein isolation; Pulmonary vein isolation with ablation.	Procedure: Pulmonary vein electrical isolation; Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy; Other Names: Pulmonary veins ablation
Experimental: Treatment arm. Radial ablation; Pulmonary vein isolation plus radial ablation of rotational activity sites.	Procedure: Radial ablation; Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Atrial fibrillation burden (1 year)	Atrial fibrillation burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial fibrillation episode. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	Patients will be followed up during one year, regardless of reaching or not the primary endpoint.
Atrial flutter burden (1 year)	Atrial flutter burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial flutter episode. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	Patients will be followed up during one year, regardless of reaching or not the primary endpoint.
Atrial tachycardia burden (1 year)	Atrial tachycardia burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial tachycardia episode. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	Patients will be followed up during one year, regardless of reaching or not the primary endpoint.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of severe complication of the ablation procedure	Occurrence of severe complications of the ablation procedure Will be identified through review of patient clinical reports. One week post-procedural complications included. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	2 years
Overall clinical procedure, radiofrequency and fluoroscopy durations	Total time registered during the clinical procedure. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	2 years
Accute procedural success rate	Accute procedural success as the percentage of episodes that revert to sinus flutter or sinus rhythm during the ablation procedure. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	2 years
Occurrence of hospitalization for cardiovascular cause	Unforeseen hospitalization for cardiovascular cause requiring overnight hospital stay during the 12 month follow-up. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	1 year
Cerebrovascular accident unforeseen hospitalization	Unforeseen hospitalization due to cerebrovascular accident (CVA) requiring overnight hospital stay during the 12 month follow-up. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	1 year
Heart failure unforeseen hospitalization	Unforeseen hospitalization due to new diagnosis for heart failure requiring overnight hospital stay during the 12 month follow-up. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	1 year
Functional class worsening unforeseen hospitalization	Unforeseen hospitalization due to functional class worsening due to heart failure requiring overnight hospital stay during the 12 month follow-up. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	1 year
Final functional class at the end of the study	Final functional class at the end of the study. New York Heart Association (NYHA) classification. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	2 years
Total and cardiac mortality	Total and cardiac mortality Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	2 years
Quality of life measured with the The Short Form (36) Health Survey	Quality of life is measured with the The Short Form (36) Health Survey at pre-specified study follow-up visits (4, 8, 12 months). The short-form (36) health survey consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. Extended analyses by gender and heart failure presence in subanalyses ARTIST-Gender and ARTIST-HF.	1 year

Collaborators and Investigators

• Sponsor: Fundacion para la Innovacion en Biomedicina (FIBMED)
• Collaborators: Hospital General Universitario Gregorio Marañon; Hospital Universitario 12 de Octubre; Puerta de Hierro University Hospital
• Investigators: Principal Investigator: Angel Arenal, MD, PhD, Hospital General Universitario Gregorio Marañón

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2022
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: November 24, 2020
• First Submitted That Met QC Criteria: December 9, 2020
• First Posted (Actual): December 10, 2020

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 10, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Atrial fibrillation; Catheter ablation; Radial ablation; Rotors
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Atrial Fibrillation
• Other Study ID Numbers: ARTIST

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No